Microbiome Drug Development Searchlight Network
At a time when milestone regulatory approvals are shaping the microbiome-based therapeutic landscape and with more companies entering the clinic, now is the time to gain momentum and succeed as a whole industry to drive awareness of the microbiome in human health.
We need to build confidence in investors, understand the regulatory environment, and demonstrate the potential of microbiome-based therapeutics in other disease indications beyond the gut.
To address some of these challenges head-on, microbiome pioneers worldwide have created the network to optimize positive clinical outcomes to accelerate safe, effective and approved microbiome-based therapeutics to patients.
Designed by and for microbiome pioneers worldwide, working across pre-clinical, translational and clinical outcomes, the network’s mission is to optimize positive clinical outcomes to accelerate safe, effective and approved microbiome-based therapeutics to patients.
CONFERENCE DAY ONE
Microbiome Drug Development Searchlight Dinner | 6.15pm
Exclusively for microbiome drug development experts with oversight of their organization's pipeline, this dinner serves to bring members and prospective members together in person, providing further opportunities to grow their networks, exchange experiences and collaborate.
IMPORTANT: We expect this experience to be in high demand, so please enquire with Searchlight@hansonwade.com for more information, for future experiences, and/or to learn more about the Microbiome Drug Development Searchlight network.
CONFERENCE DAY TWO
Microbiome Drug Development Searchlight Breakfast Taster:
How can we align on key criteria for determining engraftment and how important is this for microbiome therapeutics? | 7:00am
- Join Microbiome Drug Development Leaders at the Omni Hotel Seaport's Observatory (5th floor, Patron Tower), for a session has been built exclusively for microbiome drug development experts to share their experience on this topic in a structured way and gain a better understand of how others are viewing and tackling this key challenge.
- Despite the success of FMT as an effective treatment strategy for recurrent infections with Clostridium difficile, the factors that promote engraftment of individual strains has remained elusive and there is some disagreement on the importance of engraftment in microbiome therapeutics.
- There are some in the field that believe that engraftment is not a quantity you want as this allows you to have control over microbial exposure.
Explore Microbiome Drug Development Network
A global network of microbiome leaders united in optimizing positive clinical outcomes to accelerate safe, effective and approved microbiome-based therapeutics to patients. Joint in the mission to build confidence in investors, understand the regulatory environment, and demonstrate the potential of microbiome-based therapeutics in other disease indications beyond the gut.